Johnson & Johnson (NYSE:JNJ) Stock Holdings Lifted by FCG Investment Co

FCG Investment Co raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 219.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,409 shares of the company's stock after purchasing an additional 9,894 shares during the quarter. Johnson & Johnson accounts for about 1.5% of FCG Investment Co's holdings, making the stock its 18th biggest position. FCG Investment Co's holdings in Johnson & Johnson were worth $2,335,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its position in shares of Johnson & Johnson by 16.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company's stock valued at $3,453,978,000 after acquiring an additional 3,139,499 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Johnson & Johnson by 10.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 18,780,645 shares of the company's stock worth $2,744,979,000 after purchasing an additional 1,831,751 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Johnson & Johnson by 5.5% in the second quarter. Ameriprise Financial Inc. now owns 14,374,397 shares of the company's stock valued at $2,100,427,000 after purchasing an additional 754,200 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Johnson & Johnson by 16.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 13,147,352 shares of the company's stock worth $1,921,565,000 after buying an additional 1,829,257 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Johnson & Johnson by 5.8% in the 2nd quarter. American Century Companies Inc. now owns 8,014,213 shares of the company's stock worth $1,171,357,000 after buying an additional 437,637 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the business's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company's stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Down 0.9 %

Shares of JNJ traded down $1.51 during trading hours on Tuesday, hitting $160.09. The stock had a trading volume of 5,214,119 shares, compared to its average volume of 6,990,604. The company's fifty day simple moving average is $163.45 and its 200 day simple moving average is $155.19. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The firm has a market cap of $385.29 billion, a P/E ratio of 10.09, a P/E/G ratio of 2.90 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. The business had revenue of $22.47 billion during the quarter, compared to analysts' expectations of $22.17 billion. During the same quarter in the previous year, the business earned $2.66 EPS. The company's revenue for the quarter was up 5.2% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.10%. Johnson & Johnson's dividend payout ratio (DPR) is 30.92%.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent research reports. TD Cowen dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a "buy" rating for the company in a report on Thursday, July 18th. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 14th. Morgan Stanley raised their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 16th. The Goldman Sachs Group reduced their price objective on Johnson & Johnson from $160.00 to $155.00 and set a "neutral" rating on the stock in a research report on Friday, July 19th. Finally, Daiwa Capital Markets downgraded shares of Johnson & Johnson from an "outperform" rating to a "neutral" rating and cut their target price for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $175.93.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.